<DOC>
	<DOCNO>NCT01599819</DOCNO>
	<brief_summary>The objective study assess tolerability safety single dose treatment BAX 855 previously treat patient ( PTPs ) severe hemophilia A , determine pharmacokinetic ( PK ) parameter BAX 855 compare crossover ADVATE , evaluate impact anti-polyethylene glycol ( PEG ) antibodies PK parameter .</brief_summary>
	<brief_title>BAX 855 Dose-Escalation Safety Study</brief_title>
	<detailed_description />
	<mesh_term>Hemophilia A</mesh_term>
	<mesh_term>Factor VIII</mesh_term>
	<criteria>The subject male 18 65 year age time screen The subject severe hemophilia A ( factor VIII level &lt; 1 % ) The subject previously treat plasmaderived factor VIII ( FVIII ) concentrate recombinant FVIII least 150 exposure day ( EDs ) The subject detectable FVIII inhibitor screening , titer &gt; = 0.6 BU The subject document history FVIII inhibitor titer &gt; = 0.4 BU time prior screen The subject know hypersensitivity towards mouse hamster protein polyethylene glycol ( PEG )</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>September 2012</verification_date>
</DOC>